Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy

Trial Profile

Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2013

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors BioGeneriX; Teva Pharmaceutical Industries
  • Most Recent Events

    • 18 Nov 2013 According to the Teva Pharmaceuticals media release, the safety of Filgrastim [Granix] was evaluated in this trial and another two phase III trial in patients receiving myelosuppressive chemotherapy.
    • 07 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top